Stories & Blogs: Around the Web
| 5/18/2012 | An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA) (24/7 Wall St) |
| 5/10/2012 | Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CYTR, GALE, EXEL, GNBT, GHDX, IMGN, NKTR, NLNK, PCYC, SGEN) (24/7 Wall St) |
| 3/30/2012 | Roche and ImmunoGen need first-line data. (The Motley Fool) |
| 3/30/2012 | ImmunoGen Rally Has Legs (Barrons.com) |
| 3/30/2012 | Roche Breast-Cancer Drug Shows Trial Success (WSJ.com) |
| 3/30/2012 | Friday’s biggest gaining and declining stocks (MarketWatch.com) |
| 3/30/2012 | Stocks To Watch: Research In Motion, ImmunoGen, Finish Line (WSJ.com) |
| 3/16/2012 | Investors like Endocyte's plan. (The Motley Fool) |